Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

on of EUR 14.7 million in 2006.

About ExonHit Therapeutics

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer'disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

http://www.exonhit.com

This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... 2014 Amgen (NASDAQ: AMGN ) ... $0.61 per share dividend for the third quarter of ... 2014, to all stockholders of record as of the ... About Amgen Amgen is committed to unlocking the ... by discovering, developing, manufacturing and delivering innovative human therapeutics. ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... causes soil to release the potent greenhouse gases methane and ... Nature reveals. "This feedback to our changing atmosphere ... warming as we previously thought," said Dr Kees Jan van ... of Natural Sciences, Trinity College Dublin, and lead author of ...
... fumes could raise the risk of heart attacks, research has ... diesel burns are harmful to blood vessels and can increase ... a heart attack or stroke. The research by the ... on healthy volunteers at levels that would be found in ...
... scale, the tiniest bridge of gold -- that made of ... new research by engineers at the University at Buffalo,s Laboratory ... experiments probing the characteristics of atomic-scale necks of gold that ... pushed into a flat, gold surface. An examination of these ...
Cached Biology Technology:New research reveals soil microbes accelerate global warming 2Diesel fumes pose risk to heart as well as lungs, study shows 2Narrowest bridges of gold are also the strongest, study finds 2
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Could age of first period influence development of diseases in older women? 2
... The world is composed of multiple languages, cultures, races and ... possible that the world is more united through our ears. ... at Case Western Reserve University, proposes that our musical conceptualization ... found the commonality among children of distinct ethnic backgrounds and ...
... 31 May 2011 - Parliamentarians from across the ... today for the 17th EUREKA Inter-Parliamentary Conference. They ... market-oriented R&D projects and to ,fostering a culture ... and Technology Committee head Meir Sheetrit, in the ...
... Adelaide acoustics researchers are investigating the causes of wind ... and solving ,wind turbine syndrome,. They are also ... from wind farms so they can accurately and quickly ... methods. Research leader Dr Con Doolan, of the ...
Cached Biology News:1 world, 1 sound 21 world, 1 sound 3Noise research to combat 'wind turbine syndrome' 2
... has joined forces with the Mickle Laboratory ... Tissue Chopper. This tissue sectioning system has ... for metabolic experiments and to be especially ... at biopsy or from small organs. Its ...
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... Custom design, The Bioactive peptides are molecules ... a biological behaviour or activity which can ... pharmaceutical, diagnostic, chemical and agro-food applications. In ... modified peptides with superior properties for therapeutic ...
... are stored within neurons in vesicles ... in the synaptic bouton. Synaptosomes ... from other cellular debris. Abnormalites ... in many pathological condtions. Conditions ...
Biology Products: